Zentek (ZTEK)
NASDAQ:ZTEK
Want to see ZTEK full AI Analyst Report?
ZTEK Stock Chart & Stats
$0.69
-$0.05(-4.63%)
At close: 4:00 PM EST
$0.69
-$0.05(-4.63%)
Day’s Range― - ―
52-Week Range$0.40 - $1.84
Previous CloseN/A
Volume66.53K
Average Volume (3M)63.87K
Market Cap
$46.66M
Enterprise Value$62.48M
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$1.90M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding107,543,560
10 Day Avg. Volume35,879
30 Day Avg. Volume63,873
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)11.24
Price to Sales (P/S)190.02
P/FCF Ratio-26.38
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue66.26
Enterprise Value/Gross Profit-88.60
Enterprise Value/Ebitda-7.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthLow leverage and a meaningful asset base provide financial flexibility, lowering solvency risk and enabling the company to support R&D or partner-funded commercialization. With debt-to-equity well below 0.2, Zentek can pursue opportunities without heavy interest burdens, aiding multi‑quarter strategic plans.
Rapid Top-line AccelerationExtremely high reported revenue growth indicates early commercial traction from a small base. If this trajectory continues, it can enable scale economies, better absorption of fixed R&D/manufacturing costs, and provide a runway toward improving unit economics over the next several quarters.
IP-centric, Partnership ModelA business model emphasizing IP, licensing and partnerships reduces capital intensity and leverages external manufacturing/sales capabilities. Durable IP and partner-led commercialization can accelerate market entry, expand addressable markets and create recurring royalty or licensing revenue streams over time.
Bears Say
Small Revenue BaseRevenue remains very small relative to claimed market opportunities, limiting economies of scale and making fixed R&D and commercialization costs a heavy burden. Until revenue grows materially, margin improvement and durable profitability remain distant objectives, constraining strategic flexibility.
Negative Cash GenerationPersistent negative operating and free cash flow means the company is not self-funding operations and must rely on external financing or partnerships. Over multiple quarters this raises dilution and execution risk, and constrains the ability to fund scale-up, certifications, or manufacturing investments.
Limited Operational ScaleA small headcount indicates limited internal capacity to scale manufacturing, sales, regulatory compliance and commercialization simultaneously. This raises execution risk and increases dependence on third parties for manufacturing or market access, potentially slowing time-to-revenue expansion.
Zentek News
ZTEK FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was $0.40 and its highest was $1.84 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is $46.66M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Jul 01, 2026 which is in 60 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Feb 17, 2026. The company reported -$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.017.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 107,543,560 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.674%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in ZTEK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 3.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $37.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.65%
12-Months-Change
Fundamentals
Return on Equity
-61.26%
Trailing 12-Months
Asset Growth
-4.13%
Trailing 12-Months
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―
Ownership Overview
4.03% Insiders
0.05% Mutual Funds
0.02% Other Institutional Investors
95.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---